Board of Directors
Malin Burnham – Chair
As of January 2008, Malin Burnham is the retired chairman of John Burnham & Company Insurance and Burnham Real Estate and has been involved with these organizations since 1949. In addition to his involvement with the Burnham Companies, he has been active as a board member of several major corporations and 16 firms, in total. His present involvements include Sanford Burnham Prebys Medical Discovery Institute, the San Diego Regional Economic Development Corporation Chairman’s Competitiveness Council, the San Diego Hall of Champions Foundation, UCSD Foundation and Rady School of Management. Burnham has chaired nine major non-profits and has co-founded 14 organizations in his career, most providing direct benefit to San Diego and the nation. He is a native San Diegan who graduated from Stanford University in 1949 with a bachelor’s degree in industrial engineering.
T. Denny Sanford – Co-Chair
T. Denny Sanford is the chairman and CEO of United National Corp. A graduate of the University of Minnesota, Mr. Sanford’s career as a businessman has been complemented by his extraordinary generosity as a philanthropist. Included among the numerous recipients of Mr. Sanford’s gifts, that total more than one billion dollars, are: the Edith Sanford Foundation for Breast Cancer that was created in 2012 by a gift of $100 million in honor of Mr. Sanford’s mother who died of breast cancer when he was four years old; the Sioux Valley Hospitals and Health System, which renamed itself Sanford Health in 2007, in recognition of a $400 million gift; a $125 million gift in 2014 to establish Sanford Imagenetics, a program that will integrate genomic medicine into primary care for adults; the University of California San Diego which received a $100 million gift for the creation of the Sanford Stem Cell Clinical Center in 2013 to accelerate the translation of stem cell research discoveries by advancing clinical trials and patient therapies; the Burnham Institute for Medical Research that received a $50 million gift in 2010, and recognized its appreciation for both this and a 2008 gift of $20 million to the Sanford Center for Childhood Disease research at Burnham by then changing its name to Sanford Burnham Medical Research Institute; a $70 million gift to establish a particle physics laboratory named the Sanford Underground Research Facility; and the San Diego Consortium for Regenerative Medicine which received a gift of $30 million in 2008 and expressed its gratitude by renaming itself the Sanford Consortium for Regenerative Medicine.
Richard C. Atkinson, Ph.D.
Dr. Atkinson is president emeritus of the University of California and professor emeritus of cognitive science and psychology at the University of California, San Diego. He served as president of the UC system from 1995 to 2003, and before becoming president served for fifteen years as chancellor of UC San Diego. He is a former director of the National Science Foundation and was a long-term member of the faculty at Stanford University.
Dr. Atkinson’s scientific contributions have resulted in election to the National Academy of Sciences, the Institute of Medicine, the National Academy of Education, and the American Philosophical Society. He is past president of the American Association for the Advancement of Science, former chair of the Association of American Universities, fellow of the Center for Advanced Study in the Behavioral Sciences, the recipient of numerous honorary degrees, and a mountain in Antarctica has been named in his honor.
David Brenner, M.D.
David Brenner is vice chancellor for Health Sciences and dean of the School of Medicine at the University of California, San Diego. He earned his medical degree from the Yale University School of Medicine. After completing his residency at Yale-New Haven Medical Center, he served as a research associate in the Genetics and Biochemistry Branch of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). As vice chancellor, he leads the School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California, San Diego, and UC San Diego Health System. Dr. Brenner has oversight of more than 1300 faculty physicians, pharmacists and scientists; 7,500 staff; more than 750 medical and pharmacy students, and a health system that cares for approximately 125,000 patients annually.
A distinguished physician-scientist and leader in the field of gastroenterological research, Dr. Brenner first joined UC San Diego in 1985 as a gastroenterology fellow, later joining the School of Medicine faculty, and serving as a physician at the Veterans Affairs (VA) San Diego Healthcare System. He also served as a Pew Scholar in the Biomedical Sciences and a Clinical Investigator in the VA system. In 1993, Dr. Brenner became professor and chief of the Division of Digestive Diseases and Nutrition at the University of North Carolina at Chapel Hill, where he continued to earn accolades for his patient care and research. He was ultimately recruited to UC San Diego from the Columbia University College of Physicians and Surgeons, where from 2003 to 2007 he was Samuel Bard Professor, chair of the Department of Medicine, and physician-in-chief of New York Presbyterian Hospital/Columbia.
Dr. Brenner’s professional memberships include the American Society for Clinical Investigation; the Association of American Physicians, for which he was the president, the American College of Physicians, the American Gastroenterological Association, the American Clinical and Climatological Association, and the Institute of Medicine. He is also on the board of directors of two philanthropic foundations, the AlphaOne Foundation and the Alcoholic Beverage Medical Research Foundation. Dr. Brenner has published over 400 articles and has served on several editorial boards, including being the editor-in-chief of Gastroenterology.
Rusty Gage, Ph.D.
Rusty Gage is President of the Salk Institute. In addition, Gage is a professor and Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases in the Laboratory of Genetics. His work concentrates on the adult central nervous system and unexpected plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals. Gage’s efforts may lead to methods of replacing or enhancing brain and spinal cord tissues lost or damaged due to neurodegenerative disease or trauma. Dr. Gage earned his Ph.D. from Johns Hopkins University and completed post-doctoral work at Lund University in Sweden, under the direction of cell transplantation pioneer Anders Bjorklund.
Gage has been elected to the National Academy of Science, the Institute of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. He is also the past President of the Society for Neuroscience and recipient of the Bristol-Myers Squibb Neuroscience Award, the IPSEN Prize in Neuronal Plasticity, the Ameritec Award, the Metropolitan Life Award, the Charles A. Dana Award for Research in Aging, the Robert J. and Claire Pasarow Foundation Award, the Max-Planck Research Award, the Met-Life Award for Medical Research, the Klaus Joachim Zulch-Preis through the Max-Planck Society and the Gregory Pincus Award, and has been honored with the Christopher Reeve Research Medal.
Edward W. Holmes, M.D.
Edward W. Holmes, M.D., is a Distinguished Professor of the University of California and Vice Chancellor/Dean Emeritus of Health Sciences at UC San Diego. He is also Executive Deputy Chairman of the Biomedical Research Council and Chairman of the National Medical Research Council, Singapore.
Holmes has served on numerous advisory boards including the National Diabetes and Digestive and Kidney Diseases Advisory Council of the National Institutes of Health, the Board of Directors of Tularik, and the Scientific Advisory Board of GlaxoSmithKline which he chairs. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. He is also a Fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences.
He holds a medical degree from the University of Pennsylvania.
Ms. Keadle is an entrepreneur who has held leadership positions with several biotechnology companies, including Pharmacia AB and Invitrogen Corporation (later renamed Life Technologies, a part of the Life Sciences Solutions Group of Thermo Fisher Scientific.) Ms. Keadle earned a BA from University of California, San Diego, and worked at the Salk Institute on neuroscience research projects focusing on corticotropin-releasing factors. Actively involved with several environmental organizations, including The San Diego Ocean Discovery Institute and the San Elijo Lagoon Conservancy, Ms. Keadle is also a member of the Board of Trustees of the Salk Institute.
Pradeep K. Khosla, Ph.D.
Pradeep K. Khosla, an internationally renowned electrical and computer engineer, is the eighth Chancellor of the University of California, San Diego, and a Distinguished Professor. At UC San Diego, he has initiated a comprehensive, all-inclusive strategic planning process to develop a vision and shared goals for the future of the campus. Before his current appointment, Dr. Khosla served as Dean of the College of Engineering and Philip and Marsha Dowd University Professor at Carnegie Mellon University. There, he set the strategic direction for undergraduate and graduate education and research, and initiated undergraduate curriculum reform, successful diversity efforts, multidisciplinary research centers and graduate offerings, and international programs.
Dr. Khosla spent the majority of his career at Carnegie Mellon, rising through the ranks from his first position as Assistant Professor in 1986 to his appointment as Dean in 2004. From 1994 to 1996, he also served as a Defense Advanced Research Projects Agency (DARPA) Program Manager in the Software and Intelligent Systems Technology Office, Defense Sciences Office and Tactical Technology Office, where he managed advanced research and development programs.
Dr. Khosla received his bachelor’s degree in electrical engineering from the Indian Institute of Technology in 1980, and his MS and Ph.D. degrees in electrical and computer engineering in 1984 and 1986 at Carnegie Mellon.
Mitchell Kronenberg, Ph.D.
Dr. Kronenberg is an internationally recognized scientist and one of the most highly cited immunologists in the world. This distinction is held by less than one half of one percent of all publishing scientific authors. Dr. Kronenberg was appointed President of La Jolla Institute for Allergy & Immunology (LIAI) in September 2003. In addition to his executive duties, he serves as Chief Scientific Officer and conducts an active research program.
He received his Ph.D. from the California Institute of Technology in 1983, and stayed on to complete his postdoctoral work before joining the faculty of the UCLA School of Medicine in 1986. At UCLA, he rose through the ranks to full professor. In 1997, he came to La Jolla Institute to head the Division of Developmental Immunology, a position he held for 14 years, before stepping down recently to devote more time to his duties as President and Chief Scientific Officer.
Over the years, Dr. Kronenberg has received many major awards, most recently a prestigious Merit Award for scientific achievement from the National Institutes of Health. He has also been a Burroughs Wellcome Fund Visiting Professor at Harvard University and recently was asked to deliver the Joseph S. Ingraham immunology lecture at the Indiana University School of Medicine.
Peter G. Schultz, Ph.D.
Dr. Schultz is CEO of Scripps Research and Scripps Family Chair Professor of Chemistry. He earned his Ph.D. from the California Institute of Technology; was a postdoctoral scholar at the Massachusetts Institute of Technology; was Professor of Chemistry at the University of California at Berkeley; was a Principal Investigator at Lawrence Berkeley National Laboratory and an Investigator of the Howard Hughes Medical Institute; was founder and Institute Director of the Genomics Institute of the Novartis Research Foundation and the California Institute for Biomedical Research (CALIBR); and a founder of Affymax Research Institute, Syrrx, Kalypsys, Phenomix, SymyxTherapeutics, Ilypsa, Ambrx, Ardelyx, and Wildcat Technologies, pioneers in the application of diversity based approaches to problems in chemistry, materials science and medicine.
Dr. Schultz’ awards include the Waterman Award of the National Science Foundation, membership in the National Academy of Sciences and National Institute of Medicine, the Wolf Prize in Chemistry, the Paul Ehrlich Prize, the Arthur C. Cope Award of the American Chemical Society, and the Solvay Prize. He has coauthored 500 scientific publications and trained over 300+ graduate students and postdoctoral fellows, many of whom are on the faculties of major research institutions around the world.
Kristiina Vuori, M.D., Ph.D.
Kristiina Vuori is President of Sanford Burnham Prebys Medical Discovery Institute, Professor, and Pauline & Stanley Foster Presidential Chair. She earned her M.D. and Ph.D. degrees at University of Oulu, Finland. She received postdoctoral training at SBP in 1992-1995. Dr. Vuori was appointed to SB faculty in 1996. She was appointed Deputy Director of the Institute’s NCI-designated Cancer Center in 2003, and served as Director of the Cancer Center in 2005-2013. Dr. Vuori has been President of the Institute since 2010. She was appointed interim CEO in January, 2013.
Dr. Vuori has received numerous research grants and awards from NIH, NCI, DoD, and is an investigator of the Stand Up To Cancer Dream Team. She serves on numerous advisory capacities to NCI and other cancer organizations. She has served on several NIH and DoD study sections, and serves on Board of Directors for American Association for Cancer Research and California Institute for Regenerative Medicine. She also serves on numerous editorial boards, scientific advisory boards, and as a consultant for pharmaceutical companies. Additionally, she is co-founder of three biotechnology companies. Orally bioavailable drugs to combat chemotherapy-induced anemia that have been developed based on Dr. Vuori’s discoveries are currently
in phase II trials.